$3.77
2.45% yesterday
Nasdaq, Nov 26, 10:00 pm CET
ISIN
IL0011326795
Symbol
PYPD

Polypid Ltd Stock price

$3.80
+0.19 5.26% 1M
+1.02 36.69% 6M
+0.76 25.00% YTD
+0.30 8.42% 1Y
-19.00 83.33% 3Y
-329.20 98.86% 5Y
-566.20 99.33% 10Y
-566.20 99.33% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
+0.12 3.26%
ISIN
IL0011326795
Symbol
PYPD
Industry

Key metrics

Basic
Market capitalization
$60.4m
Enterprise Value
$37.5m
Net debt
positive
Cash
$29.5m
Shares outstanding
15.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
3.0
Financial Health
Equity Ratio
30.5%
Return on Equity
-377.4%
ROCE
-132.9%
ROIC
-
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $-22.4m
EBIT
$-32.6m | $-31.2m
Net Income
$-34.5m | $-39.1m
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | 14.9%
EBIT
-37.6% | -11.5%
Net Income
-39.8% | -34.7%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.7
FCF per Share
-
Short interest
0.4%
Employees
59
Rev per Employee
$0.0
Show more

Is Polypid Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,049 stocks worldwide.

Polypid Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Polypid Ltd forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Polypid Ltd forecast:

Buy
90%
Hold
10%

Financial data from Polypid Ltd

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.25 7.25
33% 33%
-
- Research and Development Expense 25 25
39% 39%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -33 -33
38% 38%
-
Net Profit -35 -35
40% 40%
-

In millions USD.

Don't miss a Thing! We will send you all news about Polypid Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Polypid Ltd Stock News

Neutral
GlobeNewsWire
2 days ago
Internationally recognized colorectal surgeon Steven D. Wexner, MD, FACS, FRCS, to discuss the clinical and economic burden of surgical site infections and the therapeutic potential of D-PLEX₁₀₀ Internationally recognized colorectal surgeon Steven D. Wexner, MD, FACS, FRCS, to discuss the clinical and economic burden of surgical site infections and the therapeutic potential of D-PLEX₁₀₀
Neutral
Seeking Alpha
15 days ago
PolyPid Ltd. ( PYPD ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Dikla Akselbrad - CEO & Director Ori Warshavsky - Chief Operating Officer - US Jonny Missulawin - Chief Financial Officer Conference Call Participants Yehuda Leibler Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Brandon Folkes - H.C.
Neutral
GlobeNewsWire
15 days ago
Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026
More Polypid Ltd News

Company Profile

PolyPid Ltd. develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix platform. Its products include D-PLEX, an antibiotic drug reservoir that is implanted during surgery to prevent and treat surgical site infections; D-PLEX100 for the prevention of post-abdominal surgery incisional infection; BONYPID-1000, an antibiotic eluting ß tri-calcium phosphate granule for bone related infections applications; and BONYPID–500, an antibiotic eluting bone graft substitute that fills and reconstructs periodontal and oral/maxillofacial defects, while protecting from infections. PolyPid Ltd. was founded in 2008 and is headquartered in Petach Tikva, Israel.

Head office Israel
CEO Dikla Akselbrad
Employees 59
Founded 2008
Website www.polypid.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today